Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies

Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.

Drug Safety Cancer

Can UK Biopharma Learn From Flagship Pioneering And Make ‘Bigger Leaps’?

UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.

Commercial Companies

Can GSK’s Blenrep Make A Comeback After Beating Darzalex? Eye Toxicity Concerns Remain

GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.

Clinical Trials Companies

As Biopharma Adopts Generative AI, The ‘People Element’ Is Crucial To Success

After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.

Commercial Clinical Trials

Syncona Buys Out Ailing Gene Therapy Company Freeline

Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.

Companies Financing

Flagship’s Latest Company To Search Somatic Genome To Find New Drugs

Quotient Therapeutics is the fifth new start-up unveiled by Flagship this year, and will be co-located in the US and UK to tap into leading academic genomic expertise.

StartUps and SMEs Companies
See All